Lung and Colon Cancers (Expanded Panel) 384HT Mutation PCR Array

Research Area

Browse by Pathway

Browse by Disease

Human

qBiomarker Somatic Mutation PCR Array: Human Lung and Colon Cancers (Expanded Panel) 384HT
The Human Lung and Colon Cancer (Expanded Panel) qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate and comprehensive profiling of the recurrent somatic mutations in human lung and colon cancer samples in 29 key genes: AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CTNNB1, EGFR, ERBB2, EZH2, FBXW7, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MET, NRAS, PIK3CA, PTEN, RET, SRC, STK11/LKB, and P53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The human Lung and Colon Cancer (Expanded Panel) qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in the context of lung and colon cancers and has the potential for discovery and verification of drug target biomarkers for these cancer types and other cancer types in which these mutations have been identified. This array includes 353 DNA sequence mutation assays designed to detect recurrent, functionally verified, and biologically significant mutations in human lung and colon cancers. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent recurring somatic mutations compiled from over 13000 lung cancer and 29000 colon cancer samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.

Assay Functional Annotations

How It Works

References

Resources

Modify this Array

(Number of mutation assays for each gene follows the gene symbol)

ABL1	8
AKT1	1
ALK	2
BRAF	13
CBL	4
CRLF2	1
CSF1R	1
CTNNB1	34
EGFR	30
ERBB2	3
FBXW7	6
FGFR2	1
FGFR3	8
FLT3	4
GNAQ	3
GNAS	6
HRAS	13
JAK2	7
KIT	31
KRAS	21
MEK1	4
MET	4
NOTCH1	8
NOTCH2	1
NRAS	17
PDGFRA	7
PIK3CA	30
PTCH1	2
PTEN	16
PTPN11	15
RET	7
SRC	1
STK11	7
TP53	32

Assay Functional Annotations

How It Works

References

Resources

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®

Back to Top

Assay Functional Annotations

How It Works

References

Resources

The PKB/AKT pathway in cancer.Carnero A. Curr Pharm Des. 2010 Jan; 16(1):34-44
BRAF, a target in melanoma: implications for solid tumor drug development. Flaherty KT, McArthur G. Cancer. 2010 Jul 13. [Epub ahead of print]
Clinical relevance of KRAS in human cancers. Jancík S, Drábek J, Radzioch D, Hajdúch M. J Biomed Biotechnol. 2010; 2010:150960.
Oncogenic Ras in tumour progression and metastasis. Giehl K. Biol Chem. 2005 Mar; 386(3):193-205
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. Proc Natl Acad Sci U S A. 2009 Dec 1; 106(48):20411-6
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. Cell Cycle. 2009 May 1; 8(9):1352-8
Oncogenic mutations as predictive factors in colorectal cancer. Lièvre A, Blons H, Laurent-Puig P. Oncogene. 2010 May 27; 29(21):3033-43
PI(3)King Apart PTEN's Role in Cancer. Zhang S, Yu D. Clin Cancer Res. 2010 Jul 8. [Epub ahead of print]

Back to Top